


COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 14403

We believe that this examination of all programs distributed by us since January, 1975 shows first, that NCME programs generally do not deal with drugs and that, when they do, they are as likely to present unfavorable as favorable information about them. This bears out statements made in my May 10 testimony.

Of course, this is our own analysis and it seems to me you would very much want to make your own in order to confirm these findings. I should be pleased to make these and any other tapes available to you and I respectfully submit that it is only in an examination of these that one can find the answer to the question of whether drug company support biases the information contained in NCME programs.

I shall appreciate learning whether this information can be added to my statement and would like to know what we might do to assist the Subcommittee in its examination of our materials.

Sincerely,



Jay E. Raeben
President

JER:bp

cc: Mr. Benjamin Gordon